STATIN USE IS NOT ASSOCIATED WITH PRESENCE OF AND SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author ONI, Ebenezer
SINHA, Pragya
KARIM, Adil
BLUMENTHAL, Roger
BLAHA, Michael
AGATSTON, Arthur
CONCEICAO, Raquel
CARVALHO, Jose A. M.
NASIR, Khurram
SANTOS, Raul FMUSP-HC
dc.date.issued 2013
dc.identifier.citation JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, v.61, n.10, suppl.S, p.E1427-E1427, 2013
dc.identifier.issn 0735-1097
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/2756
dc.description.abstract Background: There exists concerns within the medical community that statin use may result in development and worsening of non alcoholic fatty liver disease (NALFD). In this study we aim to assess the association of statin use with differences in the prevalence of NALFD; and severity of liver fibrosis scores specifically in subjects with hepatic steatosis. Methods: We evaluated 6,385 healthy Brazilian subjects (43±10 years, 79% males) without clinical coronary heart disease between November 2008 and July 2010. NALFD was diagnosed by ultrasound. Severity of liver fibrosis was determined by fatty liver index = (e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference – 15.745) / (1 + e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference – 15.745) * 100 and FIB-4 (age (years) × AST [U/l]/(platelets [109/l] × (ALT [U/l])1/2). FIB-4 index<1.45 had a negative predictive value of 94.7% to exclude severe fibrosis. Results: NALFD was detected in 36% (n=2310) of participants. Overall 552 (8.7%) individuals were using statins in this cohort. Those on statins were more likely to be men, older, and have higher burden of risk factors (p<0.05). In age gender adjusted analysis the odds ratio for HS with statin use was 1.13 (0.94-1.36, p=0.19). On further adjustment for metabolic risk factors, LDL and smoking the results remained unchanged (OR: 1.08, 95% CI: 0.87-1.34, p=0.47). Among those with HS, no difference in fatty liver index was noted among those using vs not using statins (71±18 vs 69±23, p=0.18). On the other hand, FIB-4 was mildly elevated with statin use in HS individuals (1.20±0.51 vs 1.02±0.46, p1.45) was noted among those using statins (OR 0.89, 95% CI: 0.60-1.29, p=0.51). Similar results were noted in both genders. Conclusions: In summary, the results of the current report are reassuring that statin use is not associated with presence of HS or result in increased risk of fibrosis subjects with NAFLD. Further studies with follow-up of these individuals are needed to identify the risk of development and progression of NALFD with use of statins.
dc.language.iso eng
dc.publisher ELSEVIER SCIENCE INC
dc.relation.ispartof Journal of the American College of Cardiology
dc.rights restrictedAccess
dc.title STATIN USE IS NOT ASSOCIATED WITH PRESENCE OF AND SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE
dc.type conferenceObject
dc.rights.holder Copyright ELSEVIER SCIENCE INC
dc.description.conferencedate MAR 09-11, 2013
dc.description.conferencelocal San Francisco - CA, EUA
dc.description.conferencename 62nd Annual Scientific Session of the American-College-of-Cardiology
dc.type.category meeting abstract
dc.type.version publishedVersion
hcfmusp.author SANTOS, Raul:FM:MCP
hcfmusp.origem.id WOS:000316555201532
hcfmusp.publisher.city NEW YORK
hcfmusp.publisher.country USA
dc.description.index MEDLINE
hcfmusp.citation.wos 1


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics